Posted by Michael Wonder on 08 Sep 2020
NICE releases initial guidance for another indication for lenalidomide
8 September 2020 - This time, it is for use as maintenance treatment after autologous stem cell transplantation for patients with newly diagnosed multiple myeloma.
Lenalidomide is not recommended, within its marketing authorisation, as maintenance treatment after an autologous stem cell transplant for newly diagnosed multiple myeloma in adults.
The cost effectiveness estimates are uncertain. This is because of limitations in the cost effectiveness model, and because the model might not reflect what happens in the NHS in England.
